Kisspeptin is the master regulator of GnRH and reproductive hormone secretion, with therapeutic potential for both under- and over-active reproductive conditions.
Master regulator of GnRHKisspeptin controls the pulsatile release of GnRH, the hormone cascade that drives puberty, menstrual cycles, and fertility in both sexes
What the researchers found
Kisspeptin is the principal upstream regulator of GnRH secretion, critical for puberty onset, sex steroid feedback, and adult fertility in both sexes. It works through the KNDy (kisspeptin-neurokinin B-dynorphin) pathway, where neurokinin B provides stimulatory and dynorphin provides inhibitory paracrine input to control pulsatile GnRH release.
When administered to humans in various forms, routes, and doses, kisspeptin robustly stimulates LH secretion and pulse frequency. This creates two therapeutic directions: boosting LH in conditions with low pulsatility (hypothalamic amenorrhea, hypogonadotropic hypogonadism) and reducing it in conditions with excess LH (like PCOS).
Why it matters
Understanding kisspeptin's role as the master switch for reproductive hormone signaling has transformed reproductive endocrinology. It provides a more upstream and potentially more precise target than directly manipulating GnRH — opening doors for gentler IVF protocols, new treatments for infertility disorders, and novel approaches to conditions like PCOS where hormone pulsatility is disrupted.
The numbers in context
KNDy pathway: kisspeptin + neurokinin B + dynorphin · Kisspeptin stimulates LH secretion and LH pulse frequency in humans · Therapeutic targets: hypothalamic amenorrhea, hypogonadotropic hypogonadism, PCOS
How the study worked
Systematic literature review of all English-language PubMed articles through January 2014 on kisspeptin-GnRH pathway in human reproductive health, supplemented by reference list screening. Focused on human studies with supporting animal data.
Who was studied
Not applicable (systematic review of human and animal studies)
What this study cannot tell us
As a review, this synthesizes existing evidence rather than generating new data. Most kisspeptin administration studies in humans at the time were small and short-term. Long-term safety and efficacy of kisspeptin-based therapies had not been established. Some findings relied heavily on animal models that may not fully translate to humans.
How to read the evidence
This is a systematic review in Human Reproduction Update, a top-tier journal, synthesizing evidence from both human and animal studies. The robustness of kisspeptin's effect on LH secretion in human studies gives this strong evidentiary support.
When this study was published
Published in 2014, this remains a key reference for the kisspeptin-GnRH field. Since then, clinical trials have advanced kisspeptin into IVF applications and further validated the therapeutic potential described here.
The bigger picture
The kisspeptin discovery represents one of the most important advances in reproductive endocrinology in decades. It filled a critical gap in understanding how the brain controls reproduction and why conditions like hypothalamic amenorrhea occur. By 2024, kisspeptin-based approaches have progressed into clinical trials for IVF triggering and other fertility applications, with some showing promise as safer alternatives to traditional GnRH-based protocols.
Questions still open
- Can kisspeptin-based therapies replace or complement existing GnRH treatments in IVF with fewer side effects?
- Could targeting the KNDy pathway offer new treatments for PCOS by normalizing LH pulsatility?
- What are the long-term effects of manipulating kisspeptin signaling on reproductive and non-reproductive health?
Common questions
What is kisspeptin and why is it important for fertility?
Could kisspeptin be used to treat PCOS?
Read the original research
The kisspeptin-GnRH pathway in human reproductive health and disease.
Human reproduction update, 20(4), 485-500
Citation
Skorupskaite, Karolina; George, Jyothis T; Anderson, Richard A. (2014). The kisspeptin-GnRH pathway in human reproductive health and disease.. Human reproduction update, 20(4), 485-500. https://doi.org/10.1093/humupd/dmu009